AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury

March 9 2018 | Category: Product


AM-Pharma completes patient recruitment of recombinant human Alkaline Phosphatase

May 22 2017 | Category: Product


AM-Pharma publishes safety and pharmacokinetic data from Phase I recAP trial

May 10 2016 | Category: Product


AM-Pharma receives FDA fast track designation for recAP in Acute Kidney Injury

April 26 2016 | Category: Product


AM-Pharma STOP-AKI Phase II trial nominated for “Most Innovative Clinical Trial Design”

April 19 2016 | Category: Product


AM-Pharma and Pfizer Inc. shortlisted for “Best Partnership Alliance” in 2015 Scrip Awards

September 30 2015 | Category: Investor


AM-Pharma publishes further preclinical data on recAP to treat Acute Kidney Injury

September 30 2015 | Category: Product


AM-Pharma receives FDA and EMA orphan drug designation to treat hypophosphatasia

June 9 2015 | Category: Product


Pfizer Acquires Minority Interest in AM-Pharma; Secures Option to Acquire Company

May 11 2015 | Category: Investor


AM-Pharma starts Adaptive Phase II trial of recAP in Acute Kidney Injury

January 20 2015 | Category: Product


Preclinical data published on AM-Pharma’s recAP to treat ultra rare disease Hypophosphatasia

December 2 2014 | Category: Product


AM-Pharma presents preclinical data on mode-of-action for recAP in Acute Kidney Injury

November 13 2014 | Category: Product


AM-Pharma closes €12.2m financing round

September 10 2014 | Category: Investor


AM-Pharma announces positive Phase I data on recAP for Acute Kidney Injury

March 26 2014 | Category: Product


American Journal of Kidney Disease publishes review article of Alkaline Phosphatase

January 28 2014 | Category: Product


AM-Pharma presents positive data from recAP preclinical study at ASN meeting

November 8 2013 | Category: Product


AM-Pharma returns to clinic with Phase I trial of new recombinant human Alkaline Phosphatase

September 23 2013 | Category: Product


AM‐Pharma Announces Appointment of Industry Expert Guido Magni as Board Member

March 16 2012 | Category: Appointment


AM-Pharma Announces Appointment of Russell Greig as Chairman

January 4 2012 | Category: Appointment


AM-Pharma Raises €29.2m in Series D Financing

September 13 2011 | Category: Investor


AM-Pharma appoints Erik van den Berg as CEO

September 2 2011 | Category: Appointment


AM-Pharma presents positive results of its Phase II clinical trial with Alkaline Phosphatase in Acute Kidney Injury

March 10 2010 | Category: Product


AM-Pharma announces loan of up to €5 million from Dutch Government

March 19 2009 | Category: Investor


AM-Pharma announces start of second Phase II trial in Acute Renal Failure

July 9 2008 | Category: Product


AM-Pharma announces €7 million First Close of series C financing round

May 28 2008 | Category: Investor


AM-Pharma announces appointment of new VP Clinical Development

February 18 2008 | Category: Appointment


AM-Pharma announces appointment of Chief Business Officer

September 17 2007 | Category: Appointment


AM-Pharma announces €2.5 million financing

August 6 2007 | Category: Investor


AM-Pharma announces positive results of Phase IIa clinical trial with Alkaline Phosphatase for ulcerative colitis

July 6 2007 | Category: Product


AM-Pharma announces positive results of a Phase IIa clinical trial with Alkaline Phosphatase in Acute Kidney Injury

March 14 2007 | Category: Product


AM-Pharma announces the appointment of Bart Wuurman as CEO

February 7 2007 | Category: Appointment


Dutch Biopharmaceutical Company AM-Pharma announces positive results in its double-blind, placebo controlled Phase IIa Sepsis trial with Alkaline Phosphatase

October 6 2006 | Category: Product



Latest News

March 9 2018
AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury
Read more.

May 22 2017
AM-Pharma completes patient recruitment of recombinant human Alkaline Phosphatase
Read more.

News Categories

Appointment
Investor
Product

Upcoming Events

For a full list of the events we will be attending this year
Click here.